Announced
Synopsis
Pharmanovia, a global pharmaceutical company, agreed to acquire 11 central nervous system brands from Sanofi, a global healthcare company. Financial terms were not disclosed. “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium and Gardena, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs," James Burt, Pharmanovia CEO.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.